(Please click on the paper to read the abstract)

1)  Mehta AB, Rahemtulla A, Kumaran TO, Marsh GW.  Chronic subdural haematoma: possible association with chronic granulocytic leukaemia in lymphoid transformation.

British Medical Journal 291, 108 (1985)

2)  Rahemtulla A, Durrant ST, Hows JM.  Subacute encephalopathy associated with human immunodeficiency virus in haemophilia A. Subacute encephalopathy associated with human immunodeficiency virus in haemophilia A.  British Medical Journal 293, 993 (1986)


3)  Rahemtulla A, Bryceson AD, McManus DP, Ellis DS.  Albendazole in the treatment of hydatid disease.  Journal of the Royal Society  of Medicine  80, 119-20 (1987)

4)  Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB, et al.  Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. Journal of Clinical Oncology 5, 1890-9 (1987)


5)  Rahemtulla A, Durrant ST, Coonar HS, Lee KW, Gordon-Smith EC.  Zygomycosis in aplastic anaemia: response to a combined regimen of amphotericin B and antilymphocyte globulin.  European Journal of Haematology 40, 315-7 (1988)


6)  Rassool F, Foroni L, Rahemtulla A, Dreazen O, Wiedemann L, Guo AP, Legon S, Catovsky D, Luzzatto L, Goldman J.  The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region.  Cancer Genetics and Cytogenetics 32, 217-27 (1988)


7)  Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA, et al.  Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development.  Journal of Immunology  145, 20-7 (1989)


8)  Fung-Leung WP, Schilham MW, Rahemtulla A, Kündig TM, Vollenweider M, Potter J, van Ewijk W, Mak TW.  CD8 is needed for development of cytotoxic T cells but not helper T cells.  Cell.  65, 443-9 (1991)


9)  Rahemtulla A, Fung-Leung WP, Schilham MW, Kündig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM and Mak TW. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4.  Nature 353, 180-4 (1991)


10)  Wallace VA, Rahemtulla A, Timms E, Penninger J, Mak TW.  CD4 expression is differentially required for deletion of MLS-1a-reactive T cells.  Journal of Experimental Medicine 176, 1459-1463 (1992)


11)  Schilham MW, Fung-Leung WP, Rahemtulla A, Kuendig T, Zhang L, Potter J, Miller RG, Hengartner H, Mak TW.  Alloreactive cytotoxic T cells can develop and function in mice lacking both CD4 and CD8.  European Journal of   Immunology 23, 1299-1304 (1993)


12)  Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM.  Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.  Journal of Virology 68, 4700-4704 (1994)


13) Rahemtulla A, Kündig TM, Narendran A, Bachmann MF, Julius M, Paige CJ, Ohashi PS, Zinkernagel RM, Mak TW.  Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.  European Journal of Immunology 24, 2213-2218 (1994)


14) Koh DR, Ho A, Rahemtulla A, Penninger J, Mak TW.  Experimental allergic encephalomyelitis (EAE) in mice lacking CD4+ T cells.  European Journal of Immunology 24, 2250-2253 (1994)


15) Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW.  Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells.   European Journal of Immunology 25, 2558-2562 (1995)


16)  Wen T, Trümper L, Fung-Leung W, Rahemtulla A, Klein E, Klein G, Mak TW.  Requirement of the CD8+ or CD4+ T lymphocyte subsets for the rejection of lymphoma and fibrosarcoma grafts studied in gene knockout hosts.  Immunol. Lett. 61, 187-90 (1998) (1.485)


17)  Bugeon L, Hargreaves RE, Crompton T, Outram S, Rahemtulla A, Porter AC, Dallman MJ.  Selective silencing of full-length CD80 but not IgV-CD80 leads to impaired clonal deletion of self-reactive T cells and altered regulation of immune responses.  European Journal of Immunology 31, 118-7 (2001) (4.990)


18) Ensminger SM, Spriewald BM, Sorensen HV, Witzke O, Flashman EG, Bushell A, Morris PJ, Rose ML, Rahemtulla A, Wood KJ.  Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD154 costimulation.  Journal of Immunology 167, 532-41 (2001) (7.065)


19) Leung RK, Thomson K, Gallimore A, Jones E, Van den Broek M, Sierro S, Alsheikhly AR, McMichael A, Rahemtulla ADeletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment.  Nature Immunology 2, 1167-73 (2001) (17.431)


20) Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla AAutologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.  Bone Marrow Transplantation 31, 163-170 (2003) (2.172)


21) Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos G, Palermos J, Yataganas X, Goldman JM, Rahemtulla APamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.  European  Journal of  Haematology  70,  34–42 (2003) (1.714)


22)  Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM.

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.  Haematologica 88, 260-7 (2003) (3.453)


23) Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.  Blood 102, 1064-9 (2003) (10.120)


24) Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla ATartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.  International Journal of Cancer 106, 455-7 (2003) (4.375)

25) Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla ASerum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.  British Journal of Haematology 123,106-9 (2003) (3.267)


26)  de la Fuente J, Reiss S, McCloy M, Vulliamy T, Roberts IA, Rahemtulla A, Dokal I.

Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.

Bone Marrow Transplantation. 32,  653-6 (2003) (2.172)

27) Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D.  Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.  British Journal of Haematology 123,730-7 (2003) (3.267)


28) Cooke FJ, Terpos E, Boyle J, Rahemtulla A, Rogers TR.  Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin.  Clinical Microbiology and Infection. 9, 1238-41 (2003) (2.238)


29)  Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC.  Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.  Leukemia 18, 962-6 (2004) (5.810)


30) Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, Kanfer E, Goldman JM, Apperley JF, Rahemtulla AAutologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.  Leukemia  18, 1420-1426 (2004) (5.810)


31) Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.  Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).  Br J Haematol. 126, 686-9. (2004)


32) Terpos E, Politou M, Rahemtulla ATumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.  J Cancer Res Clin Oncol. 130, 623-5 (2004) (2.409)


33) Merkenschlager M, Amoils S, Roldan E, Rahemtulla A, O'connor E, Fisher AG, Brown KE.  Centromeric repositioning of coreceptor loci predicts their stable silencing and the CD4/CD8 lineage choice.  Journal of Experimental Medicine 200, 1437-44 (2004) (14.588)


34) Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT).  Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.  British Journal of Haematology 128, 496-502 (2005) (4.080)


35) Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF.  Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.  Leukemia 19, 507-12(2005) (6.612)


36) Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K.  The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.  Leukemia. 19, 1969-76 (2005) (6.612)


37) Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF.  Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.  Eur J Haematol. 75, 376-83 (2005) (2.004)


38) Patterson S, Kotsianidis I, Almeida A, Politou M, Rahemtulla A, Matthew B, Schmidt RR, Cerundolo V, Roberts IA, Karadimitris A.  Human invariant NKT cells are required for effective in vitro alloresponses.  J Immunol.  175, 5087-94 (2005) (6.387)


39) Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley JF, Rahemtulla A. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.  Acta Haematol. 114, 170-3 (2005) (1.229)


40) Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.  Leuk Lymphoma. 46, 1699-707 (2005) (1.295)


41) O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla APredictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.  Bone Marrow Transplant. 37, 731-7 (2006)


42) Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D, Gillmore J, Mathias CJ, Hawkins PN, Apperley JF.  Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.  Bone Marrow Transplant. 37, 937-43 (2006)


43) Perz JB, Kristen AV, Rahemtulla A, Parameshwar J, Sack FU, Apperley JF, Goldschmidt H, Katus HA, Dengler TJ.  Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation.  Clin Res Cardiol 95, 671-4 (2006).


44) Joshi J, Wechalekar AD, Bourdillon PJ, Joshi RP, Rahemtulla A, Hawkins PN.  Images in cardiovascular medicine. Intermittent loss of second heart sound.  Circulation 114, e612-3 (2006)


45) Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla ANo evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.  Leuk Res. 30, 240-1 (2006)


46) Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E.  Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.  Int J Cancer 119, 1728-31 (2006)


47) Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI.  The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.  Br J Haematol 134, 385-90 (2006)


48) Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.  Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.  Br J Haematol 135, 688-92 (2006)


49) Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.  LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.  Bone Marrow Transplant 39, 41-7 (2007)


50) Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F.  Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.  Leukemia. 21, 943-8 (2007)


51) Brodie C, Agrawal S, Rahemtulla A, O'Shea D, Lampert I, Naresh KN.  Multiple myeloma with bone marrow extracellular crystal deposition.  J Clin Pathol. 60, 1064-5 (2007)


52) Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN.  Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.  J Clin Pathol. 61, 213-6 (2008).


53) Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, Kotsianidis I, Abdalla S, Rahemtulla A, Karadimitris A.  Regulation of multiple myeloma survival and progression by CD1d.  Blood. 113, 2498-507 (2009)


54) Deshmukh M, Elderfield K, Rahemtulla A, Naresh KN.  Immunophenotype of neoplastic plasma cells in AL amyloidosis.  J Clin Pathol. 62, 724-30 (2009)


55) Ngo NT, Brodie C, Giles C, Horncastle D, Klammer M, Lampert IA, Rahemtulla A, Naresh KN.  The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.  J Clin Pathol. 62, 1009-15 (2009)



56) Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM.  Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.  Blood. 115, 4018-20 (2010)


57) Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K.  Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.  Blood. 116, 2033-9 (2010)


58) Garland P, Gishen P, Rahemtulla APercutaneous vertebroplasty to treat painful myelomatous vertebral deposits-long-term efficacy outcomes.  Ann Hematol. 90, 95-100 (2011)


59) Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, Rahemtulla A, Apperley JF, Naresh K, MacDonald DH, Kanfer EJ.  LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.  Hematol Oncol. 29, 75-80 (2011)


60) Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Bua M, Giles C, Apperley JF, Rahemtulla A.  High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.  Bone Marrow Transplant. 46, 364-7 (2011)


61) Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K.  Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.  Biol Blood Marrow Transplant. 17, 632-9 (2011)


62) Naresh KN, Trivedi P, Luqmani A, Rahemtulla ABone marrow aspirate and trephine biopsy findings in lymphoplasmacytic lymphoma.  Am J Hematol. 86, 311-2 (2011)


63) Byrne E, Giles C, Andrews J, Rahemtulla A, Naresh KN.  Lack of correlation between emergence of an abnormal protein band or of oligoclonal bands and survival in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation.  Haematologica 96, e29 (2011)


64) Byrne E, Naresh KN, Giles C, Rahemtulla AExcess bone marrow B-cells in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation is a biomarker for improved survival.  Br J Haematol. 155, 509-11 (2011)


65) Cook G, Liakopoulou E, Pearce R, Cavet J, Morgan GJ, Kirkland K, Lee J, Davies FE, Hall R, Rahemtulla A, Russell N, Marks DI; British Society of Blood & Marrow Transplantation Clinical Trials Committee.  Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.  Biol Blood Marrow Transplant. 17, 1638-45 (2011)


66) Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R.  EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.  Biol Blood Marrow Transplant. 18, 235-40 (2012)


67) Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J.  Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.  Bone Marrow Transplant. 47, 18-23 (2012)


68) Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla AAutologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.  Br J Haematol. 157, 125-7 (2012)


69) Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.  Blood. 119, 5030-6 (2012)


70) Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C.  Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.  Oncogene. 32, 4231-42 (2013)


71) Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, Dimopoulos M, Abdalla S, Yarranton H, Naresh K, Foroni L, Reid A, Rahemtulla A, Stumpf M, Roberts I, Karadimitris A. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.  Blood. 121, 318-28 (2013)


72) Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A.  Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.  Leuk Lymphoma 54, 2200-4 (2013)


73) Patel A, Waheed U, Brett SJ, Rahemtulla A, Apperley JF, Patel PB.  Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy.  Leuk Lymphoma 55, 198-200 (2014)


74) Innes AJ, Beattie R, Sergeant R, Ghandi D, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, Macdonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K.  Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.  Bone Marrow Transplant. 48, 1324-8(2013)


75) Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N.   Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.  PLoS One. 8, e74415 (2013)


76) Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.  Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.  Blood. 123, 697-705 (2014)


77) Bain BJ, Siow W, Rahemtulla A, Abdalla S.  Azurophilic granules in myeloma cells.

            Am J Hematol. 89, 437 (2014)

78) Pitcher D, de Mattos-Shipley K, Wang Z, Tzortzis K, Goudevenou K, Flynn H, Bohn G, Rahemtulla A, Roberts I, Snijders B, Karadimitris A, Kleijnen MF.  Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE).  Biochim Biophys Acta. [Epub ahead of print] (2014)